This page is provided for research and educational purposes only and does not provide medical advice, diagnosis, treatment recommendations, dosing instructions, or instructions for human use. Research findings should be interpreted within the population, model, formulation, route, outcomes, and study design reported by each cited source.
Ipamorelin (10 mg Vial)
Ipamorelin is a synthetic pentapeptide investigated as a growth hormone secretagogue[2]. Selectivity observed in preclinical experiments does not establish comparative human safety or a personal administration schedule.
Quick Reference
What is Ipamorelin?
Research overview based on the cited scientific literature.
• Goal: Stimulate endogenous growth hormone release to support anabolic processes related to muscle growth, fat metabolism, and tissue repair[1][2].
• Storage: Lyophilized refrigerated or frozen; reconstituted refrigerated; use within ~4 weeks.
Storage Instructions
Proper storage preserves peptide quality.
• Lyophilized: Store at 2–8 °C (35.6–46.4 °F) for short-term or −20 °C (−4 °F) for long-term storage in dry, dark conditions[10][11].
• Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within ~4 weeks with bacteriostatic water[12]. For longer storage, freeze aliquots at −20 °C (−4 °F) and avoid repeated freeze–thaw cycles[11].
• Allow vials to reach room temperature before opening to reduce condensation uptake[10].
How is Ipamorelin studied?
The cited preclinical study examined growth-hormone release in rat pituitary cells, rats and swine. Its hormone-selectivity findings must be interpreted within those experimental models[2].
In a human pharmacokinetic study, healthy male volunteers received intravenous infusions. Growth-hormone responses peaked at approximately 0.67 hours; this was not a subcutaneous administration study[4].
A 21-day experiment in young female rats evaluated subsequent growth-hormone release from pituitary cells. It does not establish a human cycling schedule[5].
A randomized postoperative-ileus study used intravenous ipamorelin in bowel-resection patients. It found no statistically significant differences in its key or secondary efficacy analyses compared with placebo[6].
What does the research report about Ipamorelin?
Observations from preclinical and clinical literature.
• Supports increases in lean body mass and improvements in recovery through GH-mediated anabolic processes[1][2].
• Enhances fat metabolism and supports favorable body composition changes over time[1].
• High selectivity for GH release with minimal impact on other hormones (ACTH, cortisol, prolactin)[1][3].
• May support improved gastric motility and digestive function[6].
• Generally well tolerated with a low incidence of side effects at typical doses[3].
• Occasional mild injection-site reactions (redness, swelling) may occur; very rare reports of water retention or increased hunger.
Research Limitations / Risk Notes
The cited studies used different experimental models, populations and routes. Animal findings and short-term intravenous studies do not establish long-term human safety, subcutaneous equivalence or a personal cycling or administration schedule[2][4][5][6].
Important Note
This content is provided for scientific research and educational purposes only. It does not provide medical advice, diagnosis, treatment, dosing, or administration instructions. The compounds discussed may be investigational and are not presented as approved for human use.
